top of page
Browse by category
Search
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events
Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...
GDF15 drug shows promise in preventing heart failure related to T2DM
A new experimental anti-obesity drug, Growth Differentiation Factor 15 (GDF15), improves diastolic heart function in mice with type 2...
Allurion submits 1st of three PMA modules to FDA
Allurion Technologies has submitted the first three modules of its premarket approval application (PMA) to the FDA for the Allurion...
Conversion from SG to Ring augmented RYGB is safe and effective
The first study to demonstrate the safety and effectiveness of a conversion from sleeve gastrectomy (SG) to a Ring-augmented Roux-en-Y...
FDA approves labelling update for VIVUS’ QSYMIA
The FDA has approved a labelling update for VIVUS’ QSYMIA (phentermine and topiramate extended-release capsules CIV) that has removed the...
Journal Watch 23/10/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
GLP-1 RAs may reduce opioid overdose risk by 40%
People with opioid or alcohol use disorder (OUD, AUD) who take glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to treat...
LRYFJ for the treatment of chronic gastric leaks after LSG
Laparoscopic Roux-en-Y fistulojejunostomy (LRYFJ) is an appropriate surgical option for the treatment of chronic gastric leaks after...
Expanding access to weight-loss drugs could save thousands of lives a year
Expanding access to the new generation of weight-loss medications could prevent more than 40,000 deaths a year in the US, according to a...
Bariatric surgery found to be more cost effective than GLP-1 RAs alone
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost effective in the long term only when combined with bariatric surgery,...
Browse by tag
bottom of page